Who are IBU BID's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, Bromfenac Ophthalmic Solution B, Bromfenac 0.075% Oph Solution, Ibuprofen Tablets, Bromfenac eye drop, Prolensa 0.07% Ophthalmic Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibu-bid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IBU BID — Competitive Intelligence Brief

IBU BID (IBU BID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Pain Management / Rheumatology.

phase 3 NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 Pain Management / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

IBU BID (IBU BID) — Pfizer. IBU BID is ibuprofen formulated for twice-daily dosing to provide sustained anti-inflammatory and analgesic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IBU BID TARGET	IBU BID	Pfizer	phase 3	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Bromfenac Ophthalmic Solution B	Bromfenac Ophthalmic Solution B	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Bromfenac 0.075% Oph Solution	Bromfenac 0.075% Oph Solution	Carolina Eyecare Physicians, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Ibuprofen Tablets	Ibuprofen Tablets	Overseas Pharmaceuticals, Ltd.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Bromfenac eye drop	Bromfenac eye drop	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Prolensa 0.07% Ophthalmic Solution	Prolensa 0.07% Ophthalmic Solution	Nicole Fram M.D.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

Depomed · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Handok Inc. · 1 drug in this class
Imprimis Pharmaceuticals, Inc. · 1 drug in this class
Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
LEO Pharma · 1 drug in this class
Novartis · 1 drug in this class
Pfizer · 1 drug in this class
University of South Alabama · 1 drug in this class
ZARS Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IBU BID — Competitive Intelligence Brief. https://druglandscape.com/ci/ibu-bid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab